Analysis

Meet The Attys Arguing Supreme Court Biosimilars Battle

Law360, New York (April 21, 2017, 5:53 PM EDT) -- The U.S. Supreme Court is set to hear a blockbuster biosimilars case with multibillion-dollar implications for consumers and Big Pharma, and the outcome may well turn on arguments delivered by powerhouse litigators for Amgen and Sandoz.

Wednesday's hotly anticipated arguments will feature opposite readings of the Biologics Price Competition and Innovation Act, which in 2010 created an approval route for lower-cost biosimilars. The duel will decide how quickly competition emerges for many of the world's priciest and best-selling drugs — competition that could help patients save thousands of dollars in copays and force brand-name drugmakers to wave goodbye to billions of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!